[CAS NO. 51-52-5]  Propylthiouracil

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [51-52-5]

Catalog
SLK-S1988
Brand
Selleck
CAS
51-52-5

DESCRIPTION [51-52-5]

Overview

MDLMFCD00006041
Molecular Weight170.23
Molecular FormulaC7H10N2OS
SMILESC(CC)C1=CC(=O)NC(=S)N1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

1 mg5 mg10 mg
1 mM5.8744 mL29.3720 mL58.7441 mL
5 mM1.1749 mL5.8744 mL11.7488 mL
10 mM0.5874 mL2.9372 mL5.8744 mL
50 mM0.1175 mL0.5874 mL1.1749 mL

Description

Propylthiouracil (NSC 6498, NSC 70461) is a and inhibitor, used to treat hyperthyroidism.

Targets

thyroperoxidase [1]5'-deiodinase [1]

In vivo

Propylthiouracil-induced hypothyroidism reduces oxidative damage in the lung, hepatic, renal and ileal tissues probably due to hypometabolism in rats, which is associated with decreased production of reactive oxygen metabolites and enhancement of antioxidant mechanisms. Propylthiouracil-induced congenital hypothyroidism upregulates vimentin phosphorylation and depletes antioxidant defenses in immature rat testis. Propylthiouracil results in lesser concentrations of thyroxine (T4) and triiodothyronine (T3), greater concentrations of follicle stimulating hormone (FSH) and luteinizing hormone (LH) peptides, and increase in steroidogenic gene expression after 12 hours and 48 hours in zebrafish. Propylthiouracil-induced hypothyroidism is associated with increased tolerance of the isolated rat heart toischaemia-reperfusion. Propylthiouracil (PTU) dramatically reduces thyroid hormones on PND21 and produced deficits in body weight that persisted to adulthood in developing rats. Propylthiouracil inhibits both the synthesis of thyroid hormones in the thyroid gland and the conversion of T4 to its active form, T3. Propylthiouracil treatment significantly increases circulating TSH at both P3 and P7. Propylthiouracil exposure of adult rats, at a dose inducing modest reductions in circulating T4 concentrations and no significant effect on brain BDNF, significantly alteres the thyroid hormones and hippocampal BDNF levels in the offspring at 3 and 7 d after birth.


Synonyms

4(1H)-Pyrimidinone, 2,3-dihydro-6-propyl-2-thioxo-
Uracil, 6-propyl-2-thio-
2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone
2-Mercapto-4-hydroxy-6-n-propylpyrimidine
Procasil
Propacil
Propycil
6-Propyl-2-thio-2,4(1H,3H)pyrimidinedione
Propylthiouracil
6-Propyl-2-thiouracil
6-Propylthiouracil
6-n-Propyl-2-thiouracil
6-n-Propylthiouracil
Prothyran
PTU
2-Thio-4-oxo-6-propyl-1,3-pyrimidine
2-Thio-6-propyl-1,3-pyrimidin-4-one
Thyreostat II
Propyl-Thyracil
2-Mercapto-4-hydroxy-6-propylpyrimidine
Prothiurone
Prothycil
Protiural
Propyl-Thiorist
Propylthiorit
Thiuragyl
Prothiucil
PTU (thyreostatic)
NSC 6498
NSC 70461
2-Mercapto-6-propylpyrimidin-4-ol
6-Propyl-2-thioxo-2,3-dihydro-1H-pyrimidin-4-one